Diamyd Medical AB Announces First Meeting With FDA To Discuss Type 1 Diabetes Clinical Program In The US

STOCKHOLM, Sweden, Dec. 15 /PRNewswire-FirstCall/ -- Diamyd Medical AB (SWEDEN NOMX: DIAM B; US ADR: DMYDY) announced today that it is submitting a Pre-IND/ End of Phase II Briefing Package with the United States Food and Drug Administration relating to a proposed type 1 diabetes clinical trial in the US. The Briefing Package is submitted in support of a meeting with the agency scheduled for January 29, 2007 in Washington DC. Both the Briefing Package and the Pre-IND/End of Phase II Meeting are important first steps in the process for seeking approval to conduct clinical studies in the US.